香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Shanghai INT Medical Instruments Co., Ltd.* 上海瑛泰醫療器械股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1501） 董事會召開日期 上海瑛泰醫療器械股份有限公司（「本公司」）董事（「董事」）會（「董事會」）謹 此宣佈，本公司將於 2025 年 8 月 28 日（星期四）舉行董事會會議，藉以（其中包括） 批准本公司及其附屬公司截至 2025 年 6 月 30 日止六個月未經審核中期業績以供發佈， 及考慮派發中期股息（如有）。 承董事會命 上海瑛泰醫療器械股份有限公司 董事長 梁棟科博士 中國上海 2025 年 8 月 18 日 於本公告日期，董事會由執行董事梁棟科博士及林森先生、非執行董事宋媛博士、王瑞 琴先生、陳紅琴女士及張泓先生，以及獨立非執行董事蹇錫高先生、許鴻群先生及徐從 禮先生組成。 * 僅供識別 ...

Company Overview - Shanghai Yingtai Medical Devices Co., Ltd. is a leading enterprise in the domestic interventional medical device sector, established in 2006 and listed on the Hong Kong Stock Exchange under the stock code 01501.HK [3] - The company has a complete industrial capability, including independent mold development, product research and development, equipment development, and sterilization [3] - Yingtai Medical has obtained various certifications, including ISO13485, CE, and FDA, with products sold in over 70 countries and regions worldwide [3] Financial Performance - As of December 31, 2024, Yingtai Medical reported total revenue of 852 million yuan, a year-on-year increase of 13.17% [2] - The net profit attributable to shareholders was 192 million yuan, reflecting a year-on-year growth of 22.66% [2] - The company's gross profit margin stands at 63.11%, with a debt-to-asset ratio of 20.95% [2] Market Position and Valuation - Yingtai Medical's price-to-earnings (P/E) ratio is 24.63, ranking 31st in the healthcare equipment and services industry, which has an average P/E ratio of -0.03 and a median of 1.37 [3] - Other companies in the same industry have varying P/E ratios, with Jingjiu Medical at 0.38, Juxing Medical Holdings at 0.4, and Yihui Group at 2.35 [3] Innovation and Development - The company operates 16 subsidiaries focusing on various fields, including cardiology, neurology, orthopedics, and urology, emphasizing innovation in product development [4] - Yingtai Medical has a strong commitment to innovation, holding 85 registered products in China, 25 CE-certified products, and 20 FDA-certified products, along with 364 authorized patents [4] - The company has received numerous honors and government project supports, including recognition as a "Little Giant" enterprise and inclusion in the S&P Global "Sustainable Development Yearbook (China Edition) 2024" [4] Workforce and Future Vision - Yingtai Medical employs over 1,700 staff, with its main production base located in Jiading District, Shanghai [5] - The company's vision is to become a globally recognized medical device group led by technological innovation, contributing to the development of the Chinese medical device industry and global health [5]

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group's self-developed drug TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.20 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD for the second quarter, returning to profitability year-on-year [1] - Sun Hung Kai Properties (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinke (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - China Star Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company for the first half of the year [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group (01177) has its self-developed drug TQ05105 (JAK/ROCK inhibitor) included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.2 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD in the second quarter, returning to profitability year-on-year [1] - New World Development Company (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinkao (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - Huaxian Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Core Viewpoint - Ying Tai Medical (01501.HK) announced a conditional partnership agreement with Huai Ge Health to establish the Huai Ge Guang Tai Fund, focusing on equity investments in the medical device sector [1] Investment Details - The company will invest as a limited partner in the Huai Ge Guang Tai Fund, committing up to RMB 110 million, with an initial subscription of RMB 5 million [1] - The fund is registered in China and aims to achieve investment returns through equity investments in companies within the medical device field [1] Strategic Implications - The board believes that the investment in the Huai Ge Guang Tai Fund presents an opportunity for the company to enhance its strategic development in the medical and biotechnology sectors, improve competitiveness, and solidify its market position [1]

Group 1 - The company, Ying Tai Medical (01501), announced a conditional partnership agreement with Huige Health to establish the Huige Guangtai Fund, in which it will invest as a limited partner [1] - The company plans to invest up to RMB 110 million in the Huige Guangtai Fund, with an initial contribution of RMB 50 million [1] - The total expected subscription amount for the Huige Guangtai Fund is up to RMB 350 million, with an initial subscription amount of RMB 121 million [1] Group 2 - The primary objective of the Huige Guangtai Fund is to achieve investment returns through equity investments in companies within the medical device sector [1] - As of the announcement date, the Huige Guangtai Fund has not identified any investment targets [1] - The board believes that the investment in the Huige Guangtai Fund presents an opportunity for the company to enhance its strategic development in the medical and biotechnology sectors, improve competitiveness, and solidify its market position [1]

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 之 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 就因 本 公 告全 部 或 任 何 部分 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致之 任 何 損 失承 擔任何責任。 合夥協議 於2025年8月6日（ 交易時段後 ），本公司有條件與懷格健康（ 作為普通合夥 人及基金管理人 ）及其他有限合夥人（ 作為有限合夥人 ）訂立合夥協議，內 容 有 關 設 立 懷 格 廣 泰 基 金 並 對 其 進 行 投 資 。 本 公 司 將 以 有 限 合 夥 人之一 的身份 投資懷格 廣泰基金 ，並將 認繳出資 不超過人 民幣110.0百萬元， 其 中，首期認繳出資為人民幣50.0百萬元。 懷 格 廣 泰 基 金 將 於 中 國 註 冊 為 一 家 有 限 合 夥 企 業 ， 主 要 目 標 為 通 過 對 醫 療 器 械 領 域 的 公 司 進 行 股 權 投 資 實 現 投 資 回 報 。 截 至 本 公 告 日 期 ， 懷 格 廣泰 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海瑛泰醫療器械股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01501 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 104,213,392 | RMB | | 1 RMB | | 104,213,392 | | 2. 股份分 ...

Shanghai INT Medical Instruments Co., Ltd.* 上海瑛泰醫療器械股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1501） 將 於2025年8月29日（星 期 五）舉 行 的 2025年第一次臨時股東大會及其任何續會的委託書 本人╱吾等 （附註1） 或 ， 地址為 為本人╱吾等的股東代理人出席將於2025年8月29日（星 期 五）下 午2時正於中國上海市嘉定區金園一 路925號2幢 舉 行 的 本 公 司 臨 時 股 東 大 會（「大 會」）及 其 任 何 續 會，並 代 表 本 人╱吾 等 於 會 上 作 出 行 動， 以考慮及酌情通過召開大會通告所載的決議案 （附註5） ，並代本人╱吾等及以本人╱吾等的名稱於大會（及 其 任 何 續 會）按 下 列 指 示 就 決 議 案 投 票。 | | （附註5） 特別決議案 | （附註6） 贊 成 | 反 對 | （附註6） | 棄 權 | （附註6） | | --- | --- | --- | --- | --- | --- | --- | | 1. | 審議及批准向本公司董事會授出一般授權，以配發、 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不就因本通告全部或任何部分內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 Shanghai INT Medical Instruments Co., Ltd.* 上海瑛泰醫療器械股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：1501） 2025年第一次臨時股東大會通告 茲通告 上 海 瑛 泰 醫 療 器 械 股 份 有 限 公 司（「本公司」）將 於2025年8月29日（星 期 五）下 午2時正於中國上海市嘉定區金園一路925號2幢舉行臨時股東 大 會（「臨時股東大會」），藉 以 審 議 及 酌 情 通 過 以 下 決 議 案（無 論 有 否 修 訂）： 特別決議案 * 僅供識別 – 1 – 1. (A) 審 議 及 批 准 授 予 董 事 會 一 般 授 權，以 於 有 關 期 間 內 配 發、發 行 及 處 理 額 外 內 資 股 及╱或H ...